Mellozzan[®] (melatonin) is launched in Denmark and Norway by EQL Pharma's license partner Medice Arzneimittel Pütter GmbH & Co. KG
As the first countries outside of Sweden, EQL's key product Mellozzan[®] has now been launched in Denmark and Norway by EQL's licensee Medice. The countries are the first in a series of seven where Medice contributes its market knowledge and network to quickly reach out with Mellozzan[®] to patients. In addition to Denmark and Norway, the licensee also has ongoing work for registrations and subsequent launches in Medice's home market Germany, as well as the UK, Austria, Finland and Switzerland."The launches of Mellozzan[®] in Denmark and Norway are of great importance as milestones in our